A retrospective study analysing frequency and severity of COVID-19 differ by disease modifying therapy in patients with multiple sclerosis
Latest Information Update: 10 Jun 2021
At a glance
- Drugs Ocrelizumab (Primary) ; Rituximab (Primary) ; Fingolimod; Interferon; Natalizumab; Siponimod
- Indications Multiple sclerosis
- Focus Adverse reactions
Most Recent Events
- 10 Jun 2021 New trial record
- 22 Apr 2021 Results presented at the 73rd Annual Meeting of the American Academy of Neurology